AzTrials
AzTrials

Alcohol Use DisorderNCT06286449

Identification of Cellular and Molecular Mechanisms Involved in the Pathophysiology of Alcohol Use Disorder by Examination of Cerebrospinal Fluid

A study testing Spinal tap in people with Alcohol Use Disorder, run by Vastra Gotaland Region at 1 site in Sweden.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

BACKGROUND The brain and spinal cord are enveloped by cerebrospinal fluid (CSF), which extends down to the base of the spine, a few centimeters below the termination of the spinal cord. Here, it can be collected through a minor needle puncture. Read more about this study

Who is it for?
Ages 18 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Alcohol Use Disorder
What is being tested?
Spinal tap
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
1 siteSweden
Study dates
1 Mar 2024to 31 Dec 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • The study participant:
  • has given his/her written and oral informed consent to participate in the study
  • presents a breath alcohol concentration (BrAC) below 10mg% (10mg/dl) at the study visit

Who cannot join

  • The study participant:
  • is pregnant or breastfeeding
  • has an ongoing neurological or psychiatric disease except for Alcohol Use Disorder
  • has an ongoing or previous disease that affects either the safety of the study participant following a spinal tap or the outcome measures of the study
  • currently uses (within 30 days of enrollment) medication that affects either the safety of the study participant following a spinal tap or the outcome measures of the study
  • currently uses (within 30 days of enrollment) medications for the treatment of Alcohol Use Disorder or alcohol abstinence that affects the mesolimbic dopamine system
Show all 14Show fewer
  • currently uses (within 30 days of enrollment) dietary supplements, including energy drinks, that may affect the safety for the study participant following a spinal tap or may have an impact on the outcome measures
  • 8. currently and frequently uses (within 1 year of enrollment) drugs of abuse other than alcohol and nicotine.
  • 9. participates in another interventional clinical trial within 30 days of enrollment
  • 10. has a local infection or a tattoo in the lower back region
  • 11. anatomical anomalies in the lower spine region, e.g. following prior spine surgery, that obstructs the procedure of a spinal tap
  • 12. has prior history of allergic reactions to local anaesthetics
  • 13. presents pathological findings during medical examination that may affect the safety for the study participant following a spinal tap or the outcome measures
  • 14. is considered to be unfit for study participation for other reasons than stated above

Trial locations and contacts

1 site in 1 country.

Sweden1 site
  • Sahlgrenska Universitetssjukhuset

    Gothenburg, Västra Götaland County, 405 30

Other trials in Sweden

About this study

BACKGROUND

The brain and spinal cord are enveloped by cerebrospinal fluid (CSF), which extends down to the base of the spine, a few centimeters below the termination of the spinal cord. Here, it can be collected through a minor needle puncture. This procedure enables the gathering of information about otherwise concealed molecular and cellular processes in the brain. Analyzing various specific molecules in the CSF has yielded crucial insights into the underlying mechanisms of many neurological and psychiatric disorders, such as multiple sclerosis (MS) and dementia, significantly enhancing the prospects for its treatment. However, for several brain disorders, including Alcohol Use Disorder (AUD) and substance use disorders, CSF studies are absent. AUD, a brain disease affecting the reward system, is characterized by an inability to limit alcohol consumption. High levels of alcohol intake, as seen in AUD, are a leading cause of morbidity and premature mortality. Yet, there is a lack of effective medications for its treatment. Analyzing molecules in CSF, believed to be significant for the development and maintenance of AUD, could enhance the development of effective pharmacological treatments. At present, there are no CSF studies on individuals with AUD, that explore the underlying mechanisms of the disease. Additionally, several CSF studies lack a representative control group of truly healthy controls (i.e. have not presented any neurological or psychiatric symptoms), which is crucial for drawing accurate conclusions.

Read more

OBJECTIVE

Sub-study 1 aims to collect CSF from individuals with AUD across various ages to analyze brain molecules that contribute to the development and maintenance of the disease.

Sub-study 2 aims to gather CSF from healthy controls across various ages to study molecules involved in neurological and psychiatric conditions, including AUD, substance dependency, brain inflammation, and narcolepsy. The goal is to create a reference group of CSF from healthy controls for comparison with CSF collected from individuals with the aforementioned conditions.

We hypothesize that levels of certain molecules, such as dopamine, differ between healthy controls and those with e.g. AUD. This study may provide insights into cellular and molecular mechanisms underlying brain disorders, which is in turn crucial for developing new, effective treatments.

Sub-study 3 will examine how the incubation of nerve cells in CSF collected in sub-study 1 and 2 affects their excitability and ability to form new synapses, essential for communication in the brain.

We hypothesize that the excitability and synaptogenesis of nerve cells will vary depending on whether they are incubated in CSF from neurologically and psychiatrically healthy individuals versus those with AUD, substance use disorders, brain inflammation, and narcolepsy. Understanding how CSF composition influences brain function in these conditions could be instrumental in creating new therapeutic drugs.

METHODS

Individuals with AUD, as well as psychiatrically and neurologically healthy volunteers, will be successively recruited for CSF collection and analyses. Recruitment will be performed through media advertisements and posters within healthcare facilities (The Sahlgrenska University Hospital) and the University of Gothenburg. Additional participants will be recruited from parallel research projects performed within the group (IV-ASA BO10 dnr: 2019-04120, COMB BO8 dnr 431-18, GlycinA BO5 dnr 806-14, PI Bo Söderpalm and NordAlc BO9 dnr: 430-18, PI Andrea de Bejczy) CSF will be obtained through lumbar puncture (spinal tap), a procedure where a thin needle is inserted below the end of the spinal cord. Local anesthesia will be administered in order to mitigate potential discomfort. The lumbar puncture will be performed by an experienced physician, minimizing the risk of injury. Blood samples will also be collected to correlate molecule levels in CSF with those in the blood. Participants will be interviewed about their medical history including their alcohol consumption, and a comprehensive medical examination will be performed.

SIGNIFICANCE

CSF studies offers unique insights into the cellular and molecular processes within the brain. This approach has been utilized for exploring the mechanisms behind several psychiatric and neurological disorders, but not for certain brain diseases like AUD. AUD inflicts significant suffering for affected individuals, contributes to high mortality rates, and imposes considerable burdens on the society. Moreover, a deeper understanding of the cellular and molecular underpinnings of brain diseases such as AUD, can facilitate the development of novel, more effective medications for its treatment.

Being tested
Spinal tap
Medical subject headings
Alcoholism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Spinal tapOther

    Also called Lumbar puncture

    A spinal tap is performed on all enrolled study participants that meet the eligibility criteria

Study groups in NCT06286449
Study groupRoleWhat they receive
Alcohol Use Disorder cohort and Healthy controls cohortOtherAlcohol Use Disorder Cohort The intervention, which all participants from both cohorts undergo, consists of a spinal tap, in which 35 ml of cerebrospinal fluid is collected for further analysis and comparison between a cohort consisting of healthy controls. Study participants with Alcohol Use Disorder (AUD) are recruited from other previous or ongoing clinical trials performed within the research group: NordAlc (PI Andrea de Bejczy), IV-ASA (PI Bo Söderpalm), GlycinA (PI Bo Söderpalm) and COMB (PI Bo Söderpalm). Healthy controls cohort The intervention, which all participants from both cohorts undergo, consists of a spinal tap, in which 35 ml of cerebrospinal fluid is collected for further analysis and comparison between a cohort consisting of participants with Alcohol Use Disorder. Healthy controls will be continuously recruited via advertisements in media, and onsite at the Sahlgrenska University Hospital and the University of Gothenburg
Receives: Other: Spinal tap

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. CSF-DA levels

    Levels of dopamine in the cerebrospinal fluid

    Measured: 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Feb 2024
  2. Study start1 Mar 2024
  3. Primary completion31 Dec 2028 (estimated)
  4. Study completion31 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Model description
The intervention in this study consists of a spinal tap that all study participants undergo. We are comparing biomarkers in cerebrospinal fluid collected from either participants with Alcohol Use Disorder or from healthy controls.
Masking
None (open label)
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06286449
Sponsor's protocol ID
CSV_AUD
Status last verified
Sep 2026
First submitted
22 Feb 2024
Last updated
9 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: The ethical approval does not allow us to share individual patient data, but only data presented on a group level, so that no individual patient can be identified.

Questions about this trial

What is this clinical trial studying?

A study testing Spinal tap in people with Alcohol Use Disorder, run by Vastra Gotaland Region at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

CSF-DA levels (time frame: 3 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in